Hazardous Drug Management Systems Market Report 2026

The hazardous drug management systems market size has grown strongly in recent years. It will grow from $1.38 billion in 2025 to $1.5 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to growing focus on healthcare worker safety, increasing awareness of hazardous drug exposure risks, rising adoption of compliance-driven safety protocols, expansion of hospital and pharmacy automation, and growing enforcement of occupational safety guidelines.

The hazardous drug management systems market size is expected to see strong growth in the next few years. It will grow to $2.09 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing implementation of closed system drug transfer technologies, growing demand for automated hazardous drug handling, rising investment in oncology safety infrastructure, expansion of regulatory compliance requirements across healthcare facilities, and a rise in focus on workplace contamination prevention. Major trends in the forecast period include technology-driven innovations in closed system transfer devices, advancements in robotic and automated compounding safety solutions, developments in real-time contamination monitoring systems, rising research and development in exposure prevention technologies, and innovation in integrated hazardous drug tracking and reporting systems.

The expanding adoption of personalized medicine and increasingly complex infusion protocols is expected to drive the growth of the hazardous drug management systems market in the coming years. Personalized medicine involves tailoring medical treatments, including drug selection and dosing, based on individual patient characteristics such as genetics, biomarkers, and disease profiles. The growth of personalized medicine is fueled by the rising approval and clinical use of targeted therapies that require highly customized intravenous preparation and dosing. Hazardous drug management systems support personalized medicine by enabling the safe preparation, handling, and administration of high-potency and targeted therapies, safeguarding healthcare workers while ensuring accurate, patient-specific treatment delivery. For example, in November 2025, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the US Food and Drug Administration approved 18 new personalized medicines in 2024, representing more than 25% of all new drug approvals, following 20 approvals in 2023, many of which required individualized IV preparation. As a result, the growing use of personalized medicine and complex infusion protocols is contributing to the expansion of the hazardous drug management systems market.

The rising number of pharmaceutical clinical trials is also expected to propel the growth of the hazardous drug management systems market going forward. Pharmaceutical clinical trials are structured research studies conducted to assess the safety, effectiveness, and optimal dosing of new drugs or therapies in human participants. The increase in clinical trial activity is driven by the growing need for innovative treatments to address complex and emerging health conditions. Hazardous drug management systems support clinical trials by facilitating the safe, accurate, and compliant handling of investigational and high-potency drugs, ensuring patient safety and regulatory compliance throughout the trial process. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, the number of pharmaceutical industry trials initiated in the UK rose for the second consecutive year, increasing from 411 in 2022 to 426 in 2023. Consequently, the growing volume of pharmaceutical clinical trials is driving demand for hazardous drug management systems.

In October 2025, Ideagen PLC, a UK-based provider of software solutions for regulated and high-compliance industries, acquired SafetyStratus Inc. for an undisclosed amount. With this acquisition, Ideagen seeks to strengthen its enterprise environmental, health, and safety (EHS) portfolio by incorporating SafetyStratus’s chemical and hazardous management software, thereby expanding its capabilities in hazardous drug and chemical tracking, regulatory compliance, and safety workflows. SafetyStratus Inc. is a US-based company specializing in hazardous drug management systems, offering solutions that support the safe handling, compliance, and tracking of hazardous medications across healthcare and laboratory environments.

Major companies operating in the hazardous drug management systems market are Particle Measuring Systems Inc., Baker Hughes Company, Becton Dickinson and Company, Baxter International Inc., B. Braun Melsungen AG, Terumo Corporation, West Pharmaceutical Services Inc., ICU Medical Inc., Esco Healthcare, JMS Co. Ltd., Vygon SA, CODAN Medizinische Geräte GmbH & Co. KG, NuAire Inc., Equashield LLC, Labconco Corporation, Germfree Laboratories Inc., Sentry Air Systems Inc., Simplivia Healthcare Ltd., Mecart Cleanrooms, Corvida Medical Inc.

North America was the largest region in the hazardous drug management systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hazardous drug management systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hazardous drug management systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have impacted the hazardous drug management systems market by increasing the cost of imported automated compounding devices, closed system transfer devices, and advanced storage solutions. the rise in production and logistics costs has particularly affected regions like north america and europe, where reliance on imported specialized equipment is higher. segments such as drug compounding systems and closed system transfer devices are most affected. however, tariffs have also encouraged local manufacturing and innovation, leading to potential cost optimization and development of region-specific solutions.

Hazardous drug management systems are digital and automated solutions designed to support the safe handling, storage, preparation, tracking, and disposal of hazardous medications in regulated environments. Their primary objective is to reduce occupational exposure, prevent medication errors, and maintain compliance with safety and regulatory requirements through controlled and standardized workflows. These systems also enable real-time monitoring, audit preparedness, and risk mitigation across hazardous medication management processes.

The main types of hazardous drug management systems include closed system transfer devices, compounding systems, storage and transport systems, personal protective equipment, and others. Closed system transfer devices prevent hazardous drug vapors and liquids from escaping during handling, reducing exposure risk. Systems can be on-premises, cloud-based, or hybrid. Drug types include antineoplastic, non-antineoplastic hazardous, and reproductive-risk drugs. They support stages from procurement and compounding to administration, disposal, monitoring, and compliance, serving healthcare providers, pharmaceutical firms, research institutes, and others.

The hazardous drug management systems market consists of revenues earned by entities by providing services such as hazardous drug tracking software, safety compliance management platforms, automated workflow control systems, exposure reporting tools, and inventory monitoring solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The hazardous drug management systems also includes sales of secured storage units, automated dispensing integration systems, barcode tracking hardware, and contamination monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.